Iceland's Embla Medical Q3 sales rise on prosthetics demand

By Reuters News


Overview

  • Iceland mobility solutions firm's Q3 sales rose 5% yr/yr, driven by Prosthetics & Neuro Orthotics

  • Q3 EBITDA margin held at 22%, as cost controls offset lower gross margin

  • Company narrows 2026 guidance for organic sales growth and EBITDA margin


Outlook

  • Embla Medical narrows 2026 organic sales growth guidance to ~5% from 5-7%

  • Company narrows 2026 EBITDA margin guidance to ~21% from 20-22%


Result Drivers

  • SEGMENT PERFORMANCE - Growth in Prosthetics & Neuro Orthotics drove overall sales, with strong results in EMEA, while Americas and APAC were softer

  • PATIENT CARE FLAT - Patient Care sales were flat, with performance below expectations due to integration efforts slowing patient volume growth in some regions

  • MANUFACTURING OPTIMIZATION COSTS - Temporary costs from optimizing smaller manufacturing sites in Prosthetics business weighed on gross margin


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Sales

Miss

$250 mln

$256.50 mln (2 Analysts)

Q3 Net Income

$26 mln

Q3 Gross Margin

62.00%

Q3 EBITDA

$56 mln


Reuters Recommended Reads

  • Oct 19 - Norway's Mowi Q3 harvest volumes and EBIT hit record highs

  • Oct 19 - Sweden's Truecaller preliminary Q3 net sales rise 3% yr/yr

  • Oct 19 - Austria's BAWAG Group Q3 net profit rises, reconfirms 2026 forecast


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.